MetaVia Inc.
MTVA
Rank in Stocks
#28569
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Share Price
$1.61
Last synced: 2026-11-09
Market Cap
$10.61M
Change (1 day)
12.59%
Change (1 year)
-80.92%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade MetaVia Inc. (MTVA)
Category
Healthcare
EPS for MetaVia Inc. (MTVA)
EPS as of June 2026 TTM: $-4.07
According to MetaVia Inc.'s latest financial reports, its current EPS (TTM) is $-4.07. At the end of 2025 the company had an EPS of $-7.35, an increase over its 2024 EPS of $-39.16.
EPS history for MetaVia Inc. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-4.07 | -44.63% |
| 2025 | $-7.35 | -81.23% |
| 2024 | $-39.16 | 44.72% |
| 2023 | $-27.06 | -94.34% |
| 2022 | $-477.84 | -72.58% |
| 2021 | $-1.74K | -63.93% |
| 2020 | $-4.83K | -55.15% |
| 2019 | $-10.77K | -90.46% |
| 2018 | $-112.86K | -47.06% |
| 2017 | $-213.18K | 100.25% |
| 2016 | $-106.45K | 13.51% |
| 2015 | $-93.78K | 3,976.26% |
| 2014 | $-2.30K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -484.77% |
US
|
|
| $-7.07 | 73.71% |
US
|
|
| $-5.29 | 29.98% |
AU
|
|
| $12.88 | -416.46% |
BE
|
|
| $21.56 | -629.73% |
NL
|
Questions about MetaVia Inc.'s earnings per share (EPS)
What is MetaVia Inc.'s earnings per share (EPS)?
MetaVia Inc.'s earnings per share (EPS) over the last twelve months is $-4.07, as of Jun 2026.
What was MetaVia Inc.'s earnings per share (EPS) in 2025?
In 2025, MetaVia Inc.'s earnings per share (EPS) was $-7.35, compared with $-39.16 in 2024.
How has MetaVia Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, MetaVia Inc.'s earnings per share (EPS) was highest in 2025 ($-7.35) and lowest in 2020 ($-4.83K).
How does MetaVia Inc.'s earnings per share (EPS) compare with similar companies?
MetaVia Inc.'s earnings per share (EPS) ($-4.07) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.